Hepatitis C virus (HCV) cure before hepatocellular carcinoma (HCC) treatment is especially relevant for those patients in the early stage of the Barcelona Clinic Liver Cancer (BCLC) classification. Indeed, a major advantage with HCV cure before liver transplantation is the prevention of posttransplant HCV recurrence. Antiviral treatment of HCV after a cure of HCC is recommended by professional liver societies, owing to the fact that advanced hepatitis C complicated by liver cancer poses a substantial risk of lethal clinical decompensation if treatment of infection is deferred whereas the suppression of liver inflammation is thought to enhance the risk of developing de novo HCC. Direct-acting antiviral therapy also appears to be safe in waitlisted patients who underwent either bridge therapy or downstaging with locoablative techniques, where HCV eradication proved to be clinically advantageous.

Hepatocellular carcinoma and hepatitis C virus: which should be treated first? / M.U. Mondelli, A. Lombardi, M. Colombo - In: Clinical Dilemmas in Viral Liver Disease / [a cura di] G.R. Foster, K.R. Reddy. - Riedizione. - [s.l] : John Wiley & Sons Ltd. Published, 2020. - ISBN 9781119533399. - pp. 117-121 [10.1002/9781119533481.ch20]

Hepatocellular carcinoma and hepatitis C virus: which should be treated first?

A. Lombardi;
2020

Abstract

Hepatitis C virus (HCV) cure before hepatocellular carcinoma (HCC) treatment is especially relevant for those patients in the early stage of the Barcelona Clinic Liver Cancer (BCLC) classification. Indeed, a major advantage with HCV cure before liver transplantation is the prevention of posttransplant HCV recurrence. Antiviral treatment of HCV after a cure of HCC is recommended by professional liver societies, owing to the fact that advanced hepatitis C complicated by liver cancer poses a substantial risk of lethal clinical decompensation if treatment of infection is deferred whereas the suppression of liver inflammation is thought to enhance the risk of developing de novo HCC. Direct-acting antiviral therapy also appears to be safe in waitlisted patients who underwent either bridge therapy or downstaging with locoablative techniques, where HCV eradication proved to be clinically advantageous.
Settore MED/12 - Gastroenterologia
Book Part (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/848994
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact